Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma

被引：0
|
作者：
Veenstra, David L. [1 ]
Guzauskas, Gregory F. [1 ]
Spencer, Scott J. [1 ]
Felizzi, Federico [2 ]
Launonen, Aino [2 ]
Dawson, Keith [3 ]
Masaquel, Anthony [3 ]
机构：
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Genentech Inc, San Francisco, CA 94080 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
biosimilars; cost-effectiveness; immunochemotherapy; IBCL; indolent B-cell lymphoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-199
引用
收藏
页码：S280 / S280
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
    Spencer, Scott J.
    Guzauskas, Gregory F.
    FeLizzi, Federico
    Launonen, Aino
    Dawson, Keith
    Veenstra, David L.
    Masaquel, Anthony
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (05): : 615 - 624
  • [2] Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis
    Bellone, Marco
    Pradelli, Lorenzo
    Molica, Stefano
    De Francesco, Adele Emanuela
    Ghislieri, Daniela
    Guardalben, Emanuele
    Caputo, Antonietta
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 661 - 671
  • [3] Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients
    Ohno, Shinya
    Shoji, Ayako
    Hatake, Kiyohiko
    Oya, Naoko
    Igarashi, Ataru
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1130 - 1141
  • [4] Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Thuresson, Per-Olof
    Dawson, Keith
    Veenstra, David L.
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1668 - 1676
  • [5] Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Thuresson, Per-Olof
    Li, Jia
    Reyes, Carolina M.
    Veenstra, David
    BLOOD, 2017, 130
  • [6] Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.
    Townsend, William
    Buske, Christian
    Cartron, Guillaume
    Cunningham, David
    Dyer, Martin J. S.
    Gribben, John G.
    Zhang, Zilu
    Rufibach, Kaspar
    Nielsen, Tina
    Herold, Michael
    Hiddemann, Wolfgang
    Marcus, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] COST EFFECTIVENESS OF OBINUTUZUMAB PLUS CHEMOTHERAPY FOLLOWED BY OBINUTUZUMAB MAINTENANCE FOR PATIENT WITH PREVIOUSLY UNTREATED ADVANCED-STAGE FOLLICULAR LYMPHOMA IN FRENCH SETTING
    Mazaleyrat, B.
    Boissard, F.
    Ayad, S.
    Launonen, A.
    VALUE IN HEALTH, 2020, 23 : S438 - S438
  • [8] Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view
    Thielen, Frederick W.
    Kersten, Marie-Jose
    Kuizenga, Pim
    Hoogendoorn, Mels
    Posthuma, Eduardus F. M.
    Stevens, Wendy B. C.
    Uyl-de Groot, Carin A.
    Blommestein, Hedwig M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1411 - 1422
  • [9] COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED ITALIAN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
    Bellone, M.
    Pradelli, L.
    Friggi, E.
    Caputo, A.
    VALUE IN HEALTH, 2019, 22 : S465 - S466
  • [10] Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).
    Hardin, Colin
    Gray, Carl
    Novelli, Silvana
    Hacibekiroglu, Tuba
    Yagci, Munci
    Birhiray, Ruemu Ejedafeta
    Risal, Ashish
    Namuduri, Manjusha
    Cai, Jingxian
    Ufkin, Melanie
    Zhu, Min
    Mukherjee, Sushmita
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Iskierka-Jazdzewska, Elzbieta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345